Rami Rahal
@ratatat79
Followers
330
Following
5K
Media
50
Statuses
306
Former yeast geneticist and recovering drug hunter turned public biotech investor. Proud π±π§π¨π¦. Tweets are solely my opinions.
Joined January 2014
RT @bradloncar: PD(L)1xVEGF. ππ¨π° π’π π¬πππ«πππ: It's a fraud. ππ¨π° π’π'π¬ π π¨π’π§π : You can't afford not to own one. The first class of medicine wβ¦.
0
20
0
What a terrific Monday morning for biotech! A big congrats to our portfolio companies:.$BPMC: Acquired by Sanofi!! This one is extra special (ex BPMer).$TRVI: FIRST ever successful phase 2 for patients with IPF chronic cough!.$VERA : successful phase 3 for patients with IgAN!.
0
1
9
RT @DavidSteensma: DOGE @elonmusk approach feels like a surgeon trying to remove a small tumor using a saw instead of a scalpel, without prβ¦.
0
480
0
RT @raffcolo: MERRY CHRISTMAS everyone!. (not screaming, just all natural amino acids in their L-form π€£π
)
0
1
0
RT @paulnovosad: What kind of childhood makes a top scientist? Is it enough to have all the right traits (brilliance, grit, etc) or do youβ¦.
0
4K
0
RT @SamuelBHume: Biggest medical discoveries of the week (π§΅). 1/10. A new genetic condition, and insights into the gene that causes it: G pβ¦.
0
100
0
βthe notion that the Fed has superpowers has only become stronger over the last two decades. Pushed to explain why interest rates were at historic lows for much of the last decade, the response you often heard was "the Fed did it.β.
On Wednesday (Sept 16), after months of debate, discussion and handwringing, the Fed lowered the Fed Funds rate by half a percent. If the aftermath feels anticlimactic, it is because of the mythology around central banking:
0
0
1
RT @BertrandBio: The Emily Whitehead of Lupus is a German patient named Uresa. Need a picture with the chalkboard marked "1 year Lupus freeβ¦.
0
2
0
Finally some good news after a tough few months for biotech! M&A #4 for the year π
.
$LLY buyinng $MORF $3.2B - oral integrin for inflammatory bowel disease. $57 per share. 78% premium.
0
0
0
Best stat test! Lorlatinib > Alectinib (cross trial comp. ) but is its AE profile bad enough to give $NUVL an opportunity? π§ #ASCO24.
0
1
1
3000+% YoY increase in PIPE proceeds in 2024 but only 55% above offer price π¬. Slide courtesy of Dan Dubin/Leerink.
0
0
1
Geek out on ADC pharmacology β¬οΈ.
Nonclinical safety and PK for 14 vedotin ADCs:. - Tissue expression of the targeted antigen rarely correlated with dose-limiting toxicity. - Consistency in highest tolerated doses . - Consistency of nonclinical PK. Must read preclinical π @MCT_AACR!!!.
0
0
4
My inner geneticist is celebrating π the 12:0 YES vote for the FDA #Adcom on #MRD as an AA endpoint in #MultipleMyeloma! Important win for accelerated drug development in #biotech and for #patients . Now we wait for some other tumor typesπ€
0
0
2
